ImmunoCellular Therapeutics, Ltd. announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2017. For the quarter, the company reported loss before other income was $11,341,867 against $5,483,037 a year ago. Interest income was $381 against $6,397 a year ago. Net loss was $3,609,148 against $5,329,571 a year ago. For the period, the company reported loss before other income was $16,820,765 against $11,320,444 a year ago. Interest income was $4,175 against $8,911 a year ago. Net loss was $9,434,135 against $10,962,916 a year ago. The company used $9.5 million of cash in operations for the six months ended June 30, 2017, compared to $11.2 million for the six months ended June 30, 2016.